Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Seminars in Oncology

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 7481844
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The potential of the nude mouse xenograft model for the study of head and neck cancer

  2004cited by this paper
• Gemcitabine: current status of phase I and II trials.

  1994cited by this paper
• Clinical pharmacokinetics of anti-metabolites.

  1993cited by this paper
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

  1993cited by this paper
• Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

  1993cited by this paper
• Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts.

  1993cited by this paper
• Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

  1992cited by this paper
• In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.

  1992cited by this paper
• Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.

  1991cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

  1988cited by this paper
• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  1988cited by this paper
• Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.

  1983cited by this paper

• Tolerability and Adverse Event Profile of Fixed Dose Rate Gemcitabine in Dogs With Neoplasia.

  2026cites this paper
• Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors

  2023cites this paper
• Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

  2022cites this paper
• Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

  2022cites this paper
• PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN’S LYMPHOMA

  2021cites this paper
• Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin.

  2021cites this paper
• Effective Treatment of Undiferentiated Pleomorphic Sarcoma Using Gemcitabine: A Case Report

  2018cites this paper
• Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

  2018cites this paper
• Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.

  2017cites this paper
• A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice

  2017cites this paper
• Synthetic lethality in lung cancer and translation to clinical therapies

  2016cites this paper
• Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis

  2016cites this paper
• Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

  2015cites this paper
• Nucleoside Analog Activity in Malignant Melanoma Cell Lines

  2015cites this paper
• Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies

  2015cites this paper
• A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.

  2014cites this paper
• The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients

  2014cites this paper
• BSA-PLGA-Based Core-Shell Nanoparticles as Carrier System for Water-Soluble Drugs

  2013cites this paper
• Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer

  2013cites this paper
• Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

  2013cites this paper
• Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer

  2012cites this paper
• The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

  2012cites this paper
• Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin

  2012cites this paper
• Elective bladder preservation with multimodality treatment for bladder cancer.

  2012cites this paper
• Efficacy of a Poly‐L‐Glutamic Acid‐Gemcitabine Conjugate in Tumor‐Bearing Mice

  2012influential citation
• Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.

  2012cites this paper
• Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.

  2012cites this paper
• High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

  2012cites this paper
• Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.

  2011cites this paper
• A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

  2011influential citation
• Arguments against toxic effects of chemotherapy on liver injury and regeneration in an experimental model of partial hepatectomy

  2011cites this paper
• Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.

  2011cites this paper
• E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma.

  2011cites this paper
• A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

  2010cites this paper
• Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.

  2010cites this paper
• Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

  2010cites this paper
• Nucleoside analog cytotoxicity ‐focus on enzyme regulation, metabolism, and development of resistance

  2010cites this paper
• Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

  2010influential citation
• A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.

  2010cites this paper
• Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase

  2010cites this paper
• Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer

  2010cites this paper
• A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.

  2009cites this paper
• Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.

  2009cites this paper
• Novel therapies in peripheral T-cell lymphomas

  2008cites this paper
• Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

  2008cites this paper
• An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics

  2008cites this paper
• Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.

  2008cites this paper
• Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts

  2008cites this paper
• Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  2008cites this paper
• In vivo Hollow Fiber Assay for Anticancer Drugs' Responsiveness in a Bladder Cancer Model

  2008cites this paper
• Beyond VEGF: targeting tumor growth and angiogenesis via alternative mechanisms.

  2008cites this paper
• Novel approaches to deliver gemcitabine to cancers.

  2008cites this paper
• Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro

  2008cites this paper
• Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer Nanomedicine

  2008cites this paper
• Novel therapies in peripheral T-cell lymphomas

  2008cites this paper
• Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.

  2008cites this paper
• Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.

  2008cites this paper
• Carbohydrate antigen 19‐9‐positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine

  2007cites this paper
• Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule

  2007cites this paper
• A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

  2007cites this paper
• Gemcitabine in advanced biliary tract cancers.

  2007cites this paper
• Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects

  2007cites this paper
• Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

  2007cites this paper
• [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].

  2007cites this paper
• Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.

  2007cites this paper
• Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

  2007cites this paper
• Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

  2007cites this paper
• Phase la/lb Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer

  2006cites this paper
• A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.

  2006cites this paper
• Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

  2006cites this paper
• Schedule-dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model

  2006cites this paper
• Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate.

  2006cites this paper
• Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer

  2006cites this paper
• Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.

  2006cites this paper
• Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

  2006cites this paper
• Pancreatic cancer: basic and clinical aspects.

  2005cites this paper
• Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma

  2005cites this paper
• Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

  2005cites this paper
• Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin

  2005cites this paper
• Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines

  2005cites this paper
• Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells

  2005cites this paper
• Platinum-based chemotherapy in metastatic breast cancer: current status.

  2004cites this paper
• Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

  2004cites this paper
• Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin‐resistant human ovarian cancer (A2780/CDDP)

  2004cites this paper
• Gemcitabina como radiosensibilizante en el carcinoma no microcítico de pulmón

  2004cites this paper
• Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation.

  2004cites this paper
• A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.

  2004cites this paper
• Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.

  2004cites this paper
• Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

  2004cites this paper
• Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.

  2004cites this paper
• Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2.

  2004cites this paper
• Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.

  2003cites this paper
• Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

  2003cites this paper
• Elderly Patients with Advanced Non-Small Cell Lung Cancer

  2003cites this paper
• Preclinical antitumor activity of 4′-thio-β-d-arabinofuranosylcytosine (4′-thio-ara-C)

  2003cites this paper
• Induction of Tumor Cell Apoptosis In Vivo

  2003cites this paper
• A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.

  2003cites this paper
• Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.

  2003cites this paper
• Host Tumor-Specific CD8 T Cells Cross-Priming Rather than Cross-Tolerizing Cross-Presentation, Increases Tumor Antigen Induction of Tumor Cell Apoptosis In Vivo

  2003cites this paper
• Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.

  2003cites this paper